莱美药业：阿奇霉素颗粒获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Azithromycin granules, which is a macrolide antibiotic used for infections caused by sensitive bacteria [1] Group 1: Company Developments - The approval of Azithromycin granules will help to further enrich the company's product line [1] - A total of 41 companies have obtained the registration certificate for this drug [1] Group 2: Market Insights - According to data from Yaorongyun, the sales revenue of Azithromycin granules in the Chinese hospital market was 120 million yuan, 127 million yuan, and 95 million yuan for the years 2022, 2023, and the first half of 2024, respectively [1]